69,083 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Boston Partners

Boston Partners bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 69,083 shares of the company’s stock, valued at approximately $915,000.

A number of other institutional investors have also added to or reduced their stakes in TAK. Smithfield Trust Co increased its holdings in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after acquiring an additional 1,490 shares in the last quarter. Sage Rhino Capital LLC increased its stake in Takeda Pharmaceutical by 14.9% during the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company’s stock valued at $157,000 after purchasing an additional 1,538 shares in the last quarter. Kovitz Investment Group Partners LLC raised its holdings in Takeda Pharmaceutical by 7.0% during the third quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company’s stock worth $362,000 after buying an additional 1,670 shares during the last quarter. Aaron Wealth Advisors LLC raised its holdings in Takeda Pharmaceutical by 7.2% during the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock worth $331,000 after buying an additional 1,670 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Takeda Pharmaceutical by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company’s stock valued at $69,000 after buying an additional 1,770 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.2 %

NYSE:TAK opened at $15.20 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm has a 50-day moving average of $13.96 and a 200-day moving average of $13.92. The company has a market cap of $48.35 billion, a PE ratio of 37.99, a PEG ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.31.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.